Kimberly-Clark, the maker of household staples like Kleenex and Huggies, has announced plans to acquire Tylenol producer Kenvue in a cash and stock deal valued at approximately $48.7 billion.
The move marks one of the largest mergers in the consumer health sector, aiming to create a global powerhouse in personal care and wellness products.
Under the terms of the agreement, Kenvue shareholders will receive $3.50 per share in cash and 0.14625 Kimberly-Clark shares for each Kenvue share, totaling $21.01 per share based on Friday’s closing prices. Upon completion, Kimberly-Clark shareholders will own about 54% of the merged company, while Kenvue investors will hold roughly 46%.
The combined firm is projected to generate $32 billion in annual net revenues by 2025, supported by an estimated $1.9 billion in cost savings over the first three years after closing. Kimberly-Clark CEO Mike Hsu, who will lead the merged company, emphasized the shared vision of leveraging science and technology “to provide extraordinary care” for consumers worldwide.
The company’s headquarters will remain in Irving, Texas, while maintaining a strong operational presence at Kenvue’s existing sites. Additionally, three Kenvue board members will join Kimberly-Clark’s board, strengthening governance continuity.
Pending shareholder and regulatory approval, the deal is expected to close in the second half of next year. Following the announcement, Kimberly-Clark shares fell more than 15%, while Kenvue’s stock surged over 20%, reflecting investor reactions to the transformative merger that reshapes the landscape of consumer health and hygiene industries.
You might like this article:Reddit CEO Says AI Chatbots Aren’t Driving Traffic — Google and Direct Visits Still Lead
